Results 211 to 220 of about 6,094,547 (359)

The Provision of Alternative Cargoes [PDF]

, 1959
E. R. Hardy‐Ivamy
openalex   +1 more source

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

Molecular Oncology, EarlyView.
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton, Russell W. Madison, Candice Francheska B. Tambaoan, Funda Meric‐Bernstam, Christopher J. Sweeney, Razelle Kurzrock, Howard A. Burris III, David R. Spigel, Hanna Tukachinsky, Jason Hughes, Julia Malato, Bongin Yoo, Tania Szado, Cheryl Schwab, Lincoln W. Pasquina, Amaya Gasco, Katja Schulze, Claire F. Friedman   +17 more
wiley   +1 more source

Chronic kidney disease enhances alternative pathway activity: a new paradigm. [PDF]

J Clin Invest
Jalal DI, Thurman JM, Smith RJ.
europepmc   +1 more source

Altern

, 2020
Schweda, Mark, Schinkel, Sebastian, Hösel, Fanny, Köhler, Sina-Mareen, König, Alexandra, Schilling, Elisabeth, Schreiber, Julia, Soremski, Regina, Zschach, Maren   +8 more
openaire   +2 more sources

Dose‐dependent induction of epithelial‐mesenchymal transition in 3D melanoma models by non‐thermal plasma treatment

Molecular Oncology, EarlyView.
Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop, Edgar Cardenas De La Hoz, Hanne Verswyvel, Joey De Backer, Ho Wa Lau, Angela Privat‐Maldonado, Wim Vanden Berghe, Steve Vanlanduit, Evelien Smits, Annemie Bogaerts, Abraham Lin   +10 more
wiley   +1 more source

Alternative splicing across the C. elegans nervous system. [PDF]

Nat Commun
Weinreb A, Varol E, Barrett A, McWhirter RM, Taylor SR, Courtney I, Basavaraju M, Poff A, Tipps JA, Collings B, CeNGEN Consortium, Krishnaswamy S, Miller DM, Hammarlund M.   +13 more
europepmc   +1 more source

57: Equivalence of an implication and an alternative

, 1914
Louis Couturat
openalex   +1 more source

Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

Molecular Oncology, EarlyView.
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed, Lucas Mani, Muhammad Bilal Mirza, Ashtyn McAdoo, Takahito Kondo, Hidenori Tanaka, Nicole Meeks, Eben Rosenthal, Marisa Hom   +8 more
wiley   +1 more source

Menopause: a midlife crisis for women in India. [PDF]

BMJ Glob Health
Rajput NH.
europepmc   +1 more source

. . . economical alternative for solid and clad metals and alloys [PDF]

, 1959

openalex   +1 more source